GlaxoSmithKline CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day
GlaxoSmithKline Plc shed more light on its pipeline of experimental medicines, giving a glimpse of drugs in earlier stages of development, although analysts remain skeptical about their promise.
Glaxo has 40 drugs in the middle or final stages of clinical trials, Chief Executive Officer Andrew Witty said on Wednesday, and about half may be submitted to regulators or approved by 2020. Investors have been eager to hear more about the U.K. company’s prospects as competitors roll out cancer drugs that trigger the immune system to fight the disease.
Source: BioSpace Featured News
Ad Right Top
Extensive pharmaceutical business
October 2015 Focus: Top 50 Pharma